Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection

Table 2 Impact of precise co-morbidities on the development of sepsis

Co-morbidity	Odds ratio	95% confidence intervals	p-value
Patients with acute pyelonephritis
Type 2 diabetes mellitus	1.31	1.02–1.68	0.033
Chronic heart failure	1.93	1.39–2.69	< 0.0001
Chronic renal disease	29.31	9.26–92.86	< 0.0001
Non-metastatic solid tumor malignancy	2.03	1.40–2.89	< 0.0001
Corticosteroid intake	2.08	1.08–3.98	0.028
Stroke	1.70	1.21–2.39	0.002
Dementia	1.97	1.37–2.84	< 0.0001
Patients with community-acquired pneumonia
Type 2 diabetes mellitus	1.73	1.06–2.82	0.027
Chronic heart failure	1.99	1.13–3.49	0.016
Coronary heart disease	3.72	1.69–8.19	0.001
Dementia	3.44	1.64–7.24	0.001
Patients with intraabdominal infections
Type 2 diabetes mellitus	3.29	2.15–5.03	< 0.0001
Chronic renal disease	26.77	3.51–204.37	0.002
Corticosteroid intake	3.86	1.41–10.53	0.008
Atrial fibrillation	2.73	1.41–5.28	0.003
Dementia	9.33	3.79–22.97	< 0.0001
Liver cirrhosis	9.16	1.06–79.53	0.044
Patients with primary bacteremia
Dementia	8.55	1.12–65.20	0.038

Only variables remaining significant after the final step of logistic forward conditional regression analysis are included

ISSN: 1471-2334